-
Why Work at Eli Lilly and Company?
published: 20 Feb 2018
-
Get Better
When medicine gets better, all of us can get better.
published: 28 Jan 2024
-
Eli Lilly hits record high: Here's what investors need to know
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the company's valuation, and if there will be capacity constraints coming for healthcare companies.
published: 06 Feb 2024
-
Eli Lilly launches online direct-to-consumer pharmacy to help patients get weight loss drugs
CNBC's Bertha Coombs joins 'Squawk Box' with the latest news.
published: 04 Jan 2024
-
Why Eli Lilly is a top pick to capitalize on GLP-1 drug craze
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street.
Matt Higgins, RSE Ventures Co-Founder and CEO, joins Yahoo Finance for Good Buy or Goodbye, letting investors know which stocks to dig into and which to avoid when trying manage their portfolios.
Higgins chooses his Good Buy as Eli Lilly (LLY), citing the growth potential of GLP-1 drug market, the pipeline of obesity drugs for Eli Lilly as they continue to perfect weight-loss drugs, and the rate of obesity in America which makes for a large marketability.
Higgins picks his Goodbye as PepsiCo (PEP). Higgins argues GLP-1 users are less likely to snack, which would lead to a drop in snack food sales. Higgins al...
published: 16 Feb 2024
-
Is Eli Lilly Stock a Buy Now!? LLY Stock Analysis
🚨 Improve your investing knowledge. Free 7-Day Trial https://www.patreon.com/GlobalValue
In this video, we'll perform a LLY stock analysis and figure out what Eli Lilly looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for Eli Lilly. And answer is Eli Lilly one of the best stocks to buy at the current price? Find out in the video above! Global Value's Eli Lilly stock analysis.
Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos!
- TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue
- Check out Seekin...
published: 25 Nov 2023
-
REVEALED: I'm The Guy Behind The Viral "Insulin Is Free" Tweet
Remember the viral “insulin is free” parody tweet that set the internet ablaze? We were behind that. Here’s how our staff writer Sean exposed the greed of Elon Musk and Eli Lilly with just $8, 9 words, and 10 minutes.
UPDATE: After our tweet went viral, the three major producers of insulin all slashed prices for the drug. Here's how it happened: https://youtu.be/HVQ3-gFJPH4
#insulin #viral #twitter
-----
More Perfect Union is a new nonprofit media org with a mission to empower working people. Learn more here: http://perfectunion.us/
Follow us on Twitter: https://twitter.com/MorePerfectUS
Instagram: https://www.instagram.com/perfectunion/
Facebook: https://www.facebook.com/MorePerfUnion
published: 22 Nov 2022
-
Meet Sarkhan
Sarkhan is an AI research scientist on a mission to leverage artificial intelligence capabilities to speed up the drug discovery process, ensuring that our patients receive the life-changing medicines they need faster.
#WeAreLilly
published: 06 Feb 2024
-
Stocks: Reasons to go in on Eli Lilly stock, but avoid Tesla
The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pick for further growth can be daunting.
Which is why Public Ventures President and Chief Market Strategist Lou Basenese joins Yahoo Finance for the latest installment of Good Buy or Goodbye to help investors by giving valuable insight into which stocks stand out as the best growth picks from the S&P 500.
Basenese chooses Eli Lilly (LLY) as his Good Buy, citing the fact that the company is still in its "early stages of growth," possesses "multifaceted momentum" behind its GLP-1 weight loss drug, and a best-in-class pipeline to dominate the market versus its competition.
Basenese chooses Tesla (TSLA) as his Goodbye, citing the stock be...
published: 30 Jan 2024
-
Eli Lilly CEO talks expanding innovation past obesity drugs
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals.
Eli Lilly CEO Dave Ricks joins Yahoo Finance Health Reporter Anjalee Khemlani at the annual JPMorgan Healthcare Conference to discuss expanding the drugmaker's pipeline past obesity treatment
"If you're an investor and you're looking at Lilly, and you're thinking, this is a Zepbound-Mounjaro story, I don't think you're reading it right," Ricks says, elaborating on the other treatments Eli Lilly seeks to expand into from the success of its GLP-1s. "I think we've been on... a long climb, and it's really driven by the productivity of our R&D organization. So I think a bet on Lilly is to bet we can keep inventing new things, not just sell ...
published: 08 Jan 2024
1:01
Get Better
When medicine gets better, all of us can get better.
When medicine gets better, all of us can get better.
https://wn.com/Get_Better
When medicine gets better, all of us can get better.
- published: 28 Jan 2024
- views: 3105914
3:58
Eli Lilly hits record high: Here's what investors need to know
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings repor...
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the company's valuation, and if there will be capacity constraints coming for healthcare companies.
https://wn.com/Eli_Lilly_Hits_Record_High_Here's_What_Investors_Need_To_Know
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the company's valuation, and if there will be capacity constraints coming for healthcare companies.
- published: 06 Feb 2024
- views: 11695
7:21
Why Eli Lilly is a top pick to capitalize on GLP-1 drug craze
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector b...
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street.
Matt Higgins, RSE Ventures Co-Founder and CEO, joins Yahoo Finance for Good Buy or Goodbye, letting investors know which stocks to dig into and which to avoid when trying manage their portfolios.
Higgins chooses his Good Buy as Eli Lilly (LLY), citing the growth potential of GLP-1 drug market, the pipeline of obesity drugs for Eli Lilly as they continue to perfect weight-loss drugs, and the rate of obesity in America which makes for a large marketability.
Higgins picks his Goodbye as PepsiCo (PEP). Higgins argues GLP-1 users are less likely to snack, which would lead to a drop in snack food sales. Higgins also says that PepsiCo seems slow to pivot to healthier options and that PepsiCo has recently shown a decline in revenue.
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
https://wn.com/Why_Eli_Lilly_Is_A_Top_Pick_To_Capitalize_On_Glp_1_Drug_Craze
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street.
Matt Higgins, RSE Ventures Co-Founder and CEO, joins Yahoo Finance for Good Buy or Goodbye, letting investors know which stocks to dig into and which to avoid when trying manage their portfolios.
Higgins chooses his Good Buy as Eli Lilly (LLY), citing the growth potential of GLP-1 drug market, the pipeline of obesity drugs for Eli Lilly as they continue to perfect weight-loss drugs, and the rate of obesity in America which makes for a large marketability.
Higgins picks his Goodbye as PepsiCo (PEP). Higgins argues GLP-1 users are less likely to snack, which would lead to a drop in snack food sales. Higgins also says that PepsiCo seems slow to pivot to healthier options and that PepsiCo has recently shown a decline in revenue.
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
- published: 16 Feb 2024
- views: 1919
12:32
Is Eli Lilly Stock a Buy Now!? LLY Stock Analysis
🚨 Improve your investing knowledge. Free 7-Day Trial https://www.patreon.com/GlobalValue
In this video, we'll perform a LLY stock analysis and figure out what E...
🚨 Improve your investing knowledge. Free 7-Day Trial https://www.patreon.com/GlobalValue
In this video, we'll perform a LLY stock analysis and figure out what Eli Lilly looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for Eli Lilly. And answer is Eli Lilly one of the best stocks to buy at the current price? Find out in the video above! Global Value's Eli Lilly stock analysis.
Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos!
- TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue
- Check out Seeking Alpha Premium and score an exclusive $50 off coupon plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/
- Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!)
- Discover investing resources by shopping at my Amazon storefront! Affiliate link - https://www.amazon.com/shop/globalvalue
Eli Lilly ($LLY) | Eli Lilly Stock Fundamental Analysis | Eli Lilly Stock Dividend Analysis | Eli Lilly Dividend Analysis | $LLY Dividend Analysis | Eli Lilly Fair Value | LLY Intrinsic Value | LLY Fair Value | Eli Lilly Intrinsic Value | Eli Lilly Discounted Cash Flow Model | Eli Lilly DCF Analysis | LLY Discounted Cash Flow Analysis | LLY DCF Model
#EliLilly #LLY #LLYstock #EliLillystock #stockmarket #dividend #stocks #investing #valueinvesting #dividendstocks #investor #valueinvestor #stockanalysis #dividend #dividends #growthstocks #invest #financialeducation #finance
(Recorded November 25, 2023)
🚨⚠️ By watching videos posted on Global Value's YouTube channel, you acknowledge that you have read, understand, and agree to the following:
Global Value is Not an Investment Advisor: Global Value is not an investment adviser, and it is not registered as such with the U.S. Securities & Exchange Commission or any other state or federal authority under the Investment Advisers Act of 1940 or any other law. The investments and strategies discussed in Global Value’s YouTube videos are not and should not be considered investment advice and may not be suitable for you. They do not take into account your particular investment objectives, financial situation, needs, or personal circumstances and are not intended to be specific to you. Before acting on any investment or strategy discussed, you should always do your own research and make your own independent decision about whether it is suitable for your particular circumstances. You should also consider seeking advice from your own legal, financial, tax, accounting, or investment advisers. Global Value does not provide such advice. All content and communication from this channel is for discussion, entertainment, and illustrative purposes only and should not be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on the Channel. There are risks associated with investing in securities. Loss of principal is possible. Some high-risk investments may use leverage, which could accentuate losses. Foreign investing involves special risks, including greater volatility and political, economic, and currency risks and differences in accounting methods. Past performance is not a predictor of future investment performance. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing.
📝Contact Information:
[email protected]
https://wn.com/Is_Eli_Lilly_Stock_A_Buy_Now_Lly_Stock_Analysis
🚨 Improve your investing knowledge. Free 7-Day Trial https://www.patreon.com/GlobalValue
In this video, we'll perform a LLY stock analysis and figure out what Eli Lilly looks like based on the numbers. We'll also try to figure out what a reasonable fair intrinsic value is for Eli Lilly. And answer is Eli Lilly one of the best stocks to buy at the current price? Find out in the video above! Global Value's Eli Lilly stock analysis.
Thank you for watching. ❤️ Please support the channel by checking out our affiliates. All commissions are reinvested to improve the quality of videos!
- TIKR is the website I use for financial data in my videos. Join me and 250,000+ investors worldwide by using TIKR in your investment analysis. Referral link - https://www.tikr.com/globalvalue
- Check out Seeking Alpha Premium and score an exclusive $50 off coupon plus a free 7 day trial! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/
- Try Sharesight https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!)
- Discover investing resources by shopping at my Amazon storefront! Affiliate link - https://www.amazon.com/shop/globalvalue
Eli Lilly ($LLY) | Eli Lilly Stock Fundamental Analysis | Eli Lilly Stock Dividend Analysis | Eli Lilly Dividend Analysis | $LLY Dividend Analysis | Eli Lilly Fair Value | LLY Intrinsic Value | LLY Fair Value | Eli Lilly Intrinsic Value | Eli Lilly Discounted Cash Flow Model | Eli Lilly DCF Analysis | LLY Discounted Cash Flow Analysis | LLY DCF Model
#EliLilly #LLY #LLYstock #EliLillystock #stockmarket #dividend #stocks #investing #valueinvesting #dividendstocks #investor #valueinvestor #stockanalysis #dividend #dividends #growthstocks #invest #financialeducation #finance
(Recorded November 25, 2023)
🚨⚠️ By watching videos posted on Global Value's YouTube channel, you acknowledge that you have read, understand, and agree to the following:
Global Value is Not an Investment Advisor: Global Value is not an investment adviser, and it is not registered as such with the U.S. Securities & Exchange Commission or any other state or federal authority under the Investment Advisers Act of 1940 or any other law. The investments and strategies discussed in Global Value’s YouTube videos are not and should not be considered investment advice and may not be suitable for you. They do not take into account your particular investment objectives, financial situation, needs, or personal circumstances and are not intended to be specific to you. Before acting on any investment or strategy discussed, you should always do your own research and make your own independent decision about whether it is suitable for your particular circumstances. You should also consider seeking advice from your own legal, financial, tax, accounting, or investment advisers. Global Value does not provide such advice. All content and communication from this channel is for discussion, entertainment, and illustrative purposes only and should not be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on the Channel. There are risks associated with investing in securities. Loss of principal is possible. Some high-risk investments may use leverage, which could accentuate losses. Foreign investing involves special risks, including greater volatility and political, economic, and currency risks and differences in accounting methods. Past performance is not a predictor of future investment performance. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing.
📝Contact Information:
[email protected]
- published: 25 Nov 2023
- views: 1959
7:21
REVEALED: I'm The Guy Behind The Viral "Insulin Is Free" Tweet
Remember the viral “insulin is free” parody tweet that set the internet ablaze? We were behind that. Here’s how our staff writer Sean exposed the greed of Elon ...
Remember the viral “insulin is free” parody tweet that set the internet ablaze? We were behind that. Here’s how our staff writer Sean exposed the greed of Elon Musk and Eli Lilly with just $8, 9 words, and 10 minutes.
UPDATE: After our tweet went viral, the three major producers of insulin all slashed prices for the drug. Here's how it happened: https://youtu.be/HVQ3-gFJPH4
#insulin #viral #twitter
-----
More Perfect Union is a new nonprofit media org with a mission to empower working people. Learn more here: http://perfectunion.us/
Follow us on Twitter: https://twitter.com/MorePerfectUS
Instagram: https://www.instagram.com/perfectunion/
Facebook: https://www.facebook.com/MorePerfUnion
https://wn.com/Revealed_I'm_The_Guy_Behind_The_Viral_Insulin_Is_Free_Tweet
Remember the viral “insulin is free” parody tweet that set the internet ablaze? We were behind that. Here’s how our staff writer Sean exposed the greed of Elon Musk and Eli Lilly with just $8, 9 words, and 10 minutes.
UPDATE: After our tweet went viral, the three major producers of insulin all slashed prices for the drug. Here's how it happened: https://youtu.be/HVQ3-gFJPH4
#insulin #viral #twitter
-----
More Perfect Union is a new nonprofit media org with a mission to empower working people. Learn more here: http://perfectunion.us/
Follow us on Twitter: https://twitter.com/MorePerfectUS
Instagram: https://www.instagram.com/perfectunion/
Facebook: https://www.facebook.com/MorePerfUnion
- published: 22 Nov 2022
- views: 448333
2:08
Meet Sarkhan
Sarkhan is an AI research scientist on a mission to leverage artificial intelligence capabilities to speed up the drug discovery process, ensuring that our pati...
Sarkhan is an AI research scientist on a mission to leverage artificial intelligence capabilities to speed up the drug discovery process, ensuring that our patients receive the life-changing medicines they need faster.
#WeAreLilly
https://wn.com/Meet_Sarkhan
Sarkhan is an AI research scientist on a mission to leverage artificial intelligence capabilities to speed up the drug discovery process, ensuring that our patients receive the life-changing medicines they need faster.
#WeAreLilly
- published: 06 Feb 2024
- views: 453
6:55
Stocks: Reasons to go in on Eli Lilly stock, but avoid Tesla
The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pi...
The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pick for further growth can be daunting.
Which is why Public Ventures President and Chief Market Strategist Lou Basenese joins Yahoo Finance for the latest installment of Good Buy or Goodbye to help investors by giving valuable insight into which stocks stand out as the best growth picks from the S&P 500.
Basenese chooses Eli Lilly (LLY) as his Good Buy, citing the fact that the company is still in its "early stages of growth," possesses "multifaceted momentum" behind its GLP-1 weight loss drug, and a best-in-class pipeline to dominate the market versus its competition.
Basenese chooses Tesla (TSLA) as his Goodbye, citing the stock being overhyped and overpriced by many metrics on the fundamentals of the business, there is now a more competitive market, which the company did not have to face for years until now, and less investor confidence from business decisions made by leadership like CEO Elon Musk.
#youtube #stockmarket #Tesla
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
https://wn.com/Stocks_Reasons_To_Go_In_On_Eli_Lilly_Stock,_But_Avoid_Tesla
The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pick for further growth can be daunting.
Which is why Public Ventures President and Chief Market Strategist Lou Basenese joins Yahoo Finance for the latest installment of Good Buy or Goodbye to help investors by giving valuable insight into which stocks stand out as the best growth picks from the S&P 500.
Basenese chooses Eli Lilly (LLY) as his Good Buy, citing the fact that the company is still in its "early stages of growth," possesses "multifaceted momentum" behind its GLP-1 weight loss drug, and a best-in-class pipeline to dominate the market versus its competition.
Basenese chooses Tesla (TSLA) as his Goodbye, citing the stock being overhyped and overpriced by many metrics on the fundamentals of the business, there is now a more competitive market, which the company did not have to face for years until now, and less investor confidence from business decisions made by leadership like CEO Elon Musk.
#youtube #stockmarket #Tesla
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
- published: 30 Jan 2024
- views: 5915
11:07
Eli Lilly CEO talks expanding innovation past obesity drugs
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals.
Eli...
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals.
Eli Lilly CEO Dave Ricks joins Yahoo Finance Health Reporter Anjalee Khemlani at the annual JPMorgan Healthcare Conference to discuss expanding the drugmaker's pipeline past obesity treatment
"If you're an investor and you're looking at Lilly, and you're thinking, this is a Zepbound-Mounjaro story, I don't think you're reading it right," Ricks says, elaborating on the other treatments Eli Lilly seeks to expand into from the success of its GLP-1s. "I think we've been on... a long climb, and it's really driven by the productivity of our R&D organization. So I think a bet on Lilly is to bet we can keep inventing new things, not just sell the one we have invented, which are great as well."
#stockmarket #youtube #yahoofinance
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
https://wn.com/Eli_Lilly_Ceo_Talks_Expanding_Innovation_Past_Obesity_Drugs
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals.
Eli Lilly CEO Dave Ricks joins Yahoo Finance Health Reporter Anjalee Khemlani at the annual JPMorgan Healthcare Conference to discuss expanding the drugmaker's pipeline past obesity treatment
"If you're an investor and you're looking at Lilly, and you're thinking, this is a Zepbound-Mounjaro story, I don't think you're reading it right," Ricks says, elaborating on the other treatments Eli Lilly seeks to expand into from the success of its GLP-1s. "I think we've been on... a long climb, and it's really driven by the productivity of our R&D organization. So I think a bet on Lilly is to bet we can keep inventing new things, not just sell the one we have invented, which are great as well."
#stockmarket #youtube #yahoofinance
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
- published: 08 Jan 2024
- views: 5753